Evotec (EVO) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed Evotec (EVO) over the past year, gaining 18.6% versus a loss of 58.9%. Over five years, KMDA leads with a +49.7% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($552.6 million vs $448.4 million), about 1.2 times the size.
Kamada pays a dividend yielding 3.22%, while Evotec does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | KMDA |
|---|---|---|
| Share price | $1.56 | $7.77 |
| Market cap | $552.63M | $448.41M |
| 1-day change | -3.42% | -1.52% |
| YTD return | -47.73% | +11.76% |
| 1-year return | -58.93% | +18.65% |
| 5-year return | -92.87% | +49.72% |
| P/E ratio (TTM) | — | 20.45 |
| Forward P/E | — | 13.47 |
| EPS (TTM) | $-0.64 | $0.38 |
| Dividend yield | 0.00% | 3.22% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $4.27 | $9.35 |
| 52-week low | $1.50 | $6.55 |
| Distance from 52-week high | -63.58% | -16.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +167.52% | +73.75% |
| Average volume | 103.98K | 118.04K |
| Shares outstanding | 355.39M | 57.71M |
| Employees | 4,461 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed EVO by 77.6 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
EVO vs KMDA FAQ
Which is bigger, Evotec or Kamada?
Evotec (EVO) is larger, with a market capitalization of $552.63M compared with $448.41M for Kamada (KMDA).
Which stock has performed better over the past year, EVO or KMDA?
KMDA returned +18.65% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Evotec or Kamada?
Kamada pays a dividend yielding 3.22%, while Evotec does not currently pay a regular dividend.
Are Evotec and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.